Medical Properties Trust (MPT) Stock Forecast: What Could Drive It in 2026
Last updated July 2026
Short answer
What is actually driving Medical Properties Trust (MPT) right now is Tenant re-tenanting and rent recovery: MPT spent 2024 and 2025 replacing bankrupt Steward with new operators and is guiding toward more than $1 billion in annualized cash rent by year-end 2026. Revenue (TTM) is ~$1.0 billion. If that keeps playing out, the setup is favourable; the risk to it is mPT carries roughly $9.8 billion of debt against a market cap near $2.7 billion, so financial leverage magnifies both gains and losses and refinancing risk is real given maturities in 2026 and 2027. No one can predict where MPT trades, and Walnut does not publish targets, so treat this as a scenario, not a price target or prediction.
What could drive Medical Properties Trust (MPT) higher?
1. Tenant re-tenanting and rent recovery
MPT spent 2024 and 2025 replacing bankrupt Steward with new operators and is guiding toward more than $1 billion in annualized cash rent by year-end 2026. The thesis rests on those replacement tenants actually paying contractual rent on schedule, which would restore cash flow and support the dividend. Any slippage in cash collection directly hits funds from operations.
2. Deleveraging and refinancing runway
With roughly $9.8 billion of debt and maturities stacked through 2026 and 2027, MPT has been raising secured financing and selling assets to push out its maturity wall. Management says it has addressed near-term maturities, and each successful refinancing or asset sale reduces the risk that debt costs swamp rental income. Progress here is the single biggest lever on the equity value.
3. Deep-value and high-yield setup
The stock carries a dividend yield near 7.5 percent and trades at a mid-single-digit multiple of normalized funds from operations, well below larger healthcare REITs. For investors who believe the tenant base stabilizes, that gap is the potential re-rating. It is also one of the most heavily shorted REITs, so any confirmation of stability can move the price sharply.
4. European and behavioral health diversification
MPT holds meaningful hospital assets in the United Kingdom, Germany, and other European markets, which diversifies away from any single United States operator or reimbursement regime. A one-time United Kingdom deferred tax benefit boosted Q1 2026 results, and the behavioral health and international portfolios provide rent streams that are somewhat decoupled from the troubled United States acute care tenants.
What could weigh on MPT?
MPT carries roughly $9.8 billion of debt against a market cap near $2.7 billion, so financial leverage magnifies both gains and losses and refinancing risk is real given maturities in 2026 and 2027. Tenant concentration is a recurring problem: the 2024 Steward bankruptcy forced a dividend cut and asset sales, and in March 2026 MPT declared defaults on properties leased to Healthcare Systems of America, its third-largest tenant at about 8 percent of assets, sending the stock down about 8 percent in a day. That March 2026 disclosure triggered securities-fraud investigations by several plaintiff law firms, and MPT has faced securities litigation before tied to its 2019 to 2023 disclosures, so legal and disclosure risk is an ongoing overhang. Hospital operators face reimbursement pressure, staffing shortages, and impairments, and MPT's Q1 2026 profit relied partly on one-time tax and cash-rent items rather than durable run-rate earnings. Walnut is not an investment adviser, and these factors make MPT materially more speculative than a typical healthcare REIT.
Where MPT trades today
A forecast starts from where the stock actually is. These are MPT's current figures, not a projection: the drivers and risks above are what would move them.
Snapshot for MPT as of July 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.
How to think about a MPT forecast
Rather than chasing a price target, it tends to help to weigh the drivers above against the risks, decide how long you are willing to hold, and size the position so a wrong call is survivable. A “forecast” is really a probability-weighted view of those drivers playing out, not a number.
For the full picture, see the MPT guide and whether MPT is a buy. In Walnut you can pressure-test the thesis against your real portfolio.
The bottom line on the MPT outlook
The bottom line: what is driving Medical Properties Trust (MPT) is Tenant re-tenanting and rent recovery, with revenue (ttm) at ~$1.0 billion. If that keeps playing out the setup is favourable; the risk is mPT carries roughly $9.8 billion of debt against a market cap near $2.7 billion, so financial leverage magnifies both gains and losses and refinancing risk is real given maturities in 2026 and 2027. No one can predict the price, so treat any MPT forecast as a scenario, not a target or prediction, and decide from your own thesis and time horizon. Walnut is not an investment adviser.
More on MPT
- MPT stock guide (what the company does, ETFs that hold it, similar stocks, and the themes it fits)
- Is MPT a buy? (the case for, the risks, and a framework to decide)
- Does MPT pay a dividend?
Build a basket around MPT with Walnut
Use Medical Properties Trust as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
What is the forecast for Medical Properties Trust (MPT)?
+
No one can reliably predict where MPT will trade, and Walnut does not publish price targets. What is more useful is the setup: the drivers that could push Medical Properties Trust higher and the risks that could weigh on it. This page lays out both so you can form your own view. Not a recommendation.
What could drive MPT higher?
+
The main growth drivers are Tenant re-tenanting and rent recovery; Deleveraging and refinancing runway; Deep-value and high-yield setup. Whether they play out is the real question, not a guaranteed path.
What are the risks to MPT?
+
MPT carries roughly $9.8 billion of debt against a market cap near $2.7 billion, so financial leverage magnifies both gains and losses and refinancing risk is real given maturities in 2026 and 2027. Tenant concentration is a recurring problem: the 2024 Steward bankruptcy forced a dividend cut and asset sales, and in March 2026 MPT declared defaults on properties leased to Healthcare Systems of America, its third-largest tenant at about 8 percent of assets, sending the stock down about 8 percent in a day. That March 2026 disclosure triggered securities-fraud investigations by several plaintiff law firms, and MPT has faced securities litigation before tied to its 2019 to 2023 disclosures, so legal and disclosure risk is an ongoing overhang. Hospital operators face reimbursement pressure, staffing shortages, and impairments, and MPT's Q1 2026 profit relied partly on one-time tax and cash-rent items rather than durable run-rate earnings. Walnut is not an investment adviser, and these factors make MPT materially more speculative than a typical healthcare REIT.
Will MPT stock go up in 2026?
+
Nobody knows, and anyone who says they do is guessing. Medical Properties Trust's direction depends on whether the drivers above outweigh the risks, plus the broader market. Focus on the thesis and your time horizon rather than a single-year call.
Is MPT a buy?
+
That depends on your thesis, time horizon, and what you already own, not on a forecast. See the MPT "is it a buy?" page for a framework. Walnut is not an investment adviser.
How did MPT perform in Q1 2026?
+
MPT returned to profitability in Q1 2026, reporting about $252 million in revenue and net income of roughly $33 million, or $0.05 per share, reversing a prior-year loss. Normalized funds from operations were about $0.14 per share. The results were helped by one-time items, including a United Kingdom deferred tax benefit and cash-rent receipts.
Walnut is informational, not investment advice. This page describes drivers and risks; it is not a price forecast, target, or recommendation. Markets are uncertain and past performance does not predict future results.